Results
13
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
13 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
GALD New | CHF 97.00 | 7.5% | n/a | CHF 23.0b | CHF 99.88 | PS6x | E44.6% | n/a | Pharmaceuticals & Biotech | ||
SRAIL | CHF 19.58 | -2.3% | -36.1% | CHF 2.0b | CHF 20.60 | PE16x | E22.9% | 4.6% | Capital Goods | ||
LEHN | CHF 726.00 | -6.3% | -64.9% | CHF 826.9m | CHF 1,295.00 | PE27.1x | E37.8% | 6.9% | Tech | ||
BAER | CHF 57.62 | -2.6% | 23.2% | CHF 11.8b | CHF 61.18 | PE31.5x | E22.4% | 4.5% | Diversified Financials | ||
SQN | CHF 337.40 | -1.1% | 67.7% | CHF 5.0b | CHF 314.67 | PE19.6x | E11.8% | 1.3% | Diversified Financials | ||
YPSN | CHF 326.50 | -11.2% | 8.8% | CHF 4.5b | CHF 426.00 | PE59.9x | E41.1% | 0.6% | Healthcare | ||
COTN | CHF 247.50 | -6.1% | -8.3% | CHF 1.9b | CHF 366.14 | PE109.9x | E48.5% | 0.4% | Tech | ||
CLTN | CHF 50.40 | 1.2% | -28.0% | CHF 301.2m | CHF 62.50 | PE24.4x | E22.3% | 4.0% | Healthcare | ||
VACN | CHF 341.90 | 0.09% | -18.5% | CHF 10.3b | CHF 408.08 | PE51.2x | E21.6% | 1.8% | Capital Goods | ||
SGSN | CHF 90.24 | -0.3% | 25.0% | CHF 16.8b | CHF 92.99 | PE30.7x | E12.0% | 3.5% | Commercial Services | ||
ALSN | CHF 219.00 | -3.7% | -14.1% | CHF 2.7b | CHF 281.49 | PE25.5x | E27.6% | 2.1% | Tech | ||
SKAN New | CHF 75.20 | 2.6% | -7.5% | CHF 1.7b | CHF 90.67 | PE52.4x | E18.7% | 0.5% | Pharmaceuticals & Biotech | ||
ACLN | CHF 45.98 | -3.0% | 76.8% | CHF 4.3b | CHF 49.85 | PE33.9x | E13.5% | 1.8% | Capital Goods |